ESSA Pharma (NASDAQ:EPIX) Receives “Outperform” Rating from Oppenheimer

Oppenheimer reiterated their outperform rating on shares of ESSA Pharma (NASDAQ:EPIXFree Report) (TSE:EPI) in a research report report published on Thursday, Benzinga reports. Oppenheimer currently has a $17.00 price target on the stock.

ESSA Pharma Stock Performance

ESSA Pharma stock opened at $5.70 on Thursday. ESSA Pharma has a one year low of $2.58 and a one year high of $11.67. The company has a 50-day simple moving average of $7.55 and a 200-day simple moving average of $7.37.

Institutional Investors Weigh In On ESSA Pharma

Several large investors have recently made changes to their positions in EPIX. RTW Investments LP acquired a new position in shares of ESSA Pharma during the fourth quarter worth approximately $15,171,000. Janus Henderson Group PLC raised its stake in ESSA Pharma by 7.9% during the 1st quarter. Janus Henderson Group PLC now owns 1,175,242 shares of the company’s stock valued at $9,978,000 after acquiring an additional 85,760 shares in the last quarter. Rock Springs Capital Management LP boosted its position in ESSA Pharma by 2.1% during the 3rd quarter. Rock Springs Capital Management LP now owns 677,005 shares of the company’s stock worth $2,092,000 after acquiring an additional 13,688 shares during the period. BNP Paribas Financial Markets grew its stake in shares of ESSA Pharma by 164.9% in the fourth quarter. BNP Paribas Financial Markets now owns 57,466 shares of the company’s stock worth $379,000 after purchasing an additional 35,771 shares in the last quarter. Finally, EntryPoint Capital LLC bought a new position in shares of ESSA Pharma in the first quarter worth $38,000. Institutional investors and hedge funds own 75.12% of the company’s stock.

ESSA Pharma Company Profile

(Get Free Report)

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.

Further Reading

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.